Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT05299957 |
| Other study ID # |
201407314A3 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
August 1, 2015 |
| Est. completion date |
December 31, 2021 |
Study information
| Verified date |
July 2022 |
| Source |
Chang Gung Memorial Hospital |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Head and neck cancer (HNC) continues to be a significant health care problem in Taiwan and
oropharyngeal squamous cell carcinoma (SCC) is the common subtype. With the concern of organ
preservation in recent years, concurrent chemoradiation is the major treatment modality for
oropharyngeal SCC, while endoscopy with biopsy serves as the main diagnostic tools. With the
advance of MRI technology, whole body MRI is now possible, and functional techniques become
more feasible in the head and neck region, including diffusion-weighted imaging (DWI) which
comprises of monoexponential DWI, intravoxel incoherent motion (IVIM) model and Kurtosis
(biexponential or non-Gaussian fitting), and dynamic contrast-enhanced perfusion weighted MRI
(DCE-PWI) become feasible. Therefore, MRI can evaluate distant site status of HNC in the
single examination session and provide biologic information of tumors. Positron emission
tomography/CT (PET/CT) is another common imaging modality to evaluate HNC, because of its
ability to provide whole-body anatomic and metabolic information.
Integrated PET/MRI is a novel imaging technology that combines PET and MRI in one single
scanner. In this 3-year prospective study, the investigators will take the advantages of
integrated PET/MRI scanner with DWI (including monoexponential, kurtosis and IVIM modes) and
DCE-PWI to evaluate our 160 patients with oropharyngeal SCC subjected to chemoradiation.
Non-contrast chest CT will also be performed on the same day. The investigators aim to
determine whole-body staging/restaging accurately, to predict treatment response and
prognosis, and to determine necessity of noncontrast chest CT. The investigators expect that
this project will offer the validation of usefulness of integrated PET/MRI in tumor
staging/restaging of oropharyngeal SCC and resultant clinical impact. The role of noncontrast
chest CT in the workup with our PET/MRI protocol can be defined. It will also provide
evidence about how and to what extent the various simultaneously acquired MRI and PET
functional parameters can help prediction of treatment response and prognosis of
oropharyngeal SCC subjected to chemoradiation, which are important in timely modification of
treatment regimen.
Description:
In this three-year prospective project, a total of 160 patients with histologically proven
oropharyngeal SCC subjected to chemoradiation will be enrolled. Exclusion criteria include
previous head or neck malignant tumor, a second malignant tumor, distant metastasis,
contraindications to MRI (renal insufficiency, cochlear implant, cardiac pacemaker, or
intracranial aneurysmal ferromagnetic clips), and serum glucose level >200 mg/dl. Each
enrolled patients will undergo detail clinical examination, including human papillomavirus
test. The participants will undergo low dose chest CT on the same day before PET/MRI. In the
posttreatment period, baseline whole body MRI will be obtained 3 months after chemoradiation.
Thereafter, the participants will then be followed up also with alternative extend-field CT
and whole body MRI by every 6 months. If tumor recurrenceis confirmed or highly suspected,
PET/MRI will also be performed for tumor re-staging.
The three-years planning Adequate cases number and follow-up duration are essential for
statistical analysis and outcome determination of oropharyngeal SCC treated with
chemoradiation. The investigators plan to accomplish this study in 3 years.
In the first year, the works of the this project in the first year will design the data bank
categories, set up the workflow and optimize the imaging protocols, determine the diagnostic
capability of MRI component, PET component, integrated PET/MRI in tumor staging, determinate
any added diagnostic value of noncontrast chest CT in integrated PET/MRI, and study the early
treatment response and the patterns of residual tumor.
In the second year, the investigators will continue to the first-year works, and further
include the following works to determinate incidence and predictors of treatment failure of
oropharyngeal SCC, and to study the patterns of treatment response and early recurrence. In
the third year, the investigators will continue to do previous work and will also get
sufficient sample size to perform statistical analysis of the relationship between the
imaging parameters and patient outcomes, attain comprehensive imaging about patterns of tumor
recurrence and posttreatment changes/complications, investigate to what extent biologic
imaging parameters may affect outcome and patient selection for chemoradiation, and analysis
the accuracy, pitfalls and cost effectiveness of the PET/MRI alone and PET/MRI with
noncontrast chest CT in evaluating in patients with oropharyngeal SCC.
PET/MRI data will be acquired on the integrated PET/MRI scanner , which acquires simultaneous
PET and MR data with a 3.0-T magnet. The examination protocol will combined a whole-body scan
with a dedicated examination of the head and neck area. All participants will fast for 6 h
before the scan. At 50-70 min post injection of 370 MBq of FDG, the patient will be placed on
the PET/MRI scanner bed. After fast-view T1-weighted MR localizer sequence for scout imaging
and Dixon VIBE sequence for attenuation correction, a whole-body PET scan will be performed
in 5 bed positions to cover from the head to the proximal thigh, with an acquisition time of
4 min per bed position. Simultaneously, whole body MR image acquisition will be performed for
the corresponding 5 bed positions with the axial HASTE sequence and coronal STIR sequence as
well as the sagittal T1-weighted Turbo spine echo(TSE) and STIR sequence.
Afterwards, regional PET and MRI images will be simultaneously performed. Regional PET will
be performed with an acquisition time of 10 min, while a dedicated MRI of the head and neck
region will be acquired in the axial and coronal projections with T1-weighted TSE sequence
and T2-weighted TSE sequence with fat saturation. Axial DWI will be performed using a single
shot spin-echo echo-planar technique with modified Stejskal-Tanner diffusion gradient pulsing
scheme. A total of 10 b values will be used for the reconstruction of IVIM and kurtosis
imaging, which are: 0, 20, 40, 80, 100, 200, 400, 800, 1200, 1500 sec/mm2. DCE-PWI at the
head and neck region will be acquired by using a 3D T1-weighted spoiled gradient-echo
sequence. A spatial saturation slab will be implanted inferior to the acquired region to
minimize the inflow effect from the carotid arteries. Before the contrast agent
administration, baseline longitudinal relaxation time values will be calculated from image
acquired with different flip angles. Then, the dynamic series will be acquired using the same
sequence with a 15° flip angle, after intravenous administration of paramagnetic contrast
agent at 3 ml/s. Thereafter, dedicated regional MRI will be obtained with T1-weighted TSE
sequence with fat saturation in the axial and coronal projections. Finally, whole body axial
VIBE with fat saturation will be performed. The total acquisition time is about 42 min, and
the mean in-room time for PET/MR will be approximately 60 min.
Non-enhanced low-dose chest CT Spiral low-dose chest CT without contrast material enhancement
will be performed before PET/MRI on the same examination day. Acquisition parameters include
peak voltage of 120 kVp, mAs of 50, collimation of 64x0.5 mm and reconstruction interval of
3-mm.
Data analysis Readers are aware that patients have oropharyngeal SCC, and they will be
blinded to the results of other studies and to PET/MR data. The PET, MRI and chest CT images
will be first interpreted independently. All images will be then reviewed together and
compared. A checklist of various distributions of tumor extension, nodal spread and distant
metastasis will be recorded. The clinical and imaging findings will be discussed jointly by
the Head-and-Neck research team. Endoscopic biopsy, ultrasonographic guided fine needle
aspiration or CT-guided biopsy will be performed in any lesions suspicion for malignancy if
possible. If biopsy of the lesion of interest is not feasible, or yields a negative result,
close clinical and imaging follow-up will be pursued. All participants will be followed up
for at least 12 months. The clinical and functional imaging data will be collected and
analyzed for predicting treatment response and prognosis. For the diffusion MRI, regions of
interest will be manually placed on the lesions on ADC map to encompass as much of the solid
tumor area as possible. The signal intensities measured on the images acquired at different
b-values S(b) will be numerically fitted against the model, S(b)=S0 e-b*ADC, where S0 and Sb
are signal intensities at different b values, For IVIM imaging, the relationship between
signal intensities and b values can be expressed by the equation: Sb/S0 = (1-f )．exp(-bD) +
f．exp[-b( D + D＊)] where f is a microvascular volume fraction representing the fraction of
the diffusion linked to microcirculation, D represents pure diffusion coefficient, and D* is
perfusion-related incoherent microcirculation. For the DKI, the relationship between signal
intensities and b values can be expressed by the equation: ln[S(b)] = ln[S(0)] - b x Dapp +
1/6b2 x Dapp2 x Kapp where S is the signal intensity (arbitrary units), b is the b-value
(s/mm2), Dapp is the apparent diffusion coefficient (10-3 mm2/s), and Kapp is the apparent
kurtosis coefficient denoting thedeviation from a Gaussian distribution. We will also perform
monoexponential fitting by using Kapp=0 in the equation, yielding ADCmono. For the DCE-PWI
MRI, the change in contrast agent concentration over time, Ct(t), will be determined in each
voxel in the tumor, and the compartmental tracer kinetic model will be applied to each voxel
by using an arterial input function, Cp(t), measured in each individual: Ct (t)=VpCp(t) +
Ktrans ∫0 t Cp(t' ) exp(Ktrans(t-t') /Ve )dt' where t' is the time (in minutes) as an
integration variable, and Cp(t') is the concentration of contrast agent in the blood plasma
as a function of time.
For PET imaging parameters, SUV and MTV of the target lesions will be measured from
attenuation-corrected 18F-FDG PET images by drawing the boundaries drawn large enough to
include the lesions. An SUV threshold of 2.5 will be used to delineate the MTV. The TLG is
calculated as the product of the mean SUV and the MTV.
